2. UroToday Home
  3. Transformative Evidence
  4. The VISION Trial: Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
  5. Articles
  6. UroToday
  7. Prostate Cancer

Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes - Beyond the Abstract

177Lu-PSMA therapy is an effective treatment in patients with metastatic castration-resistant prostate cancer. SUVmean is a valuable screening biomarker to assess the suitability for 177Lu-PSMA therapy but requires quantitative software.

Click here to view Beyond the Abstract Slides:


Mina Swiha, MD, PhD, St. Vincent Hospital, Sydney, Australia

Read the Abstract


Related Content:

SNMMI 2024: Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu PSMA Therapy: Comparison to Quantitative SUVmean and Patient Outcomes